Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America

被引：0

作者：

Costagliola, D ^{[1
]}

Dabis, F ^{[1
]}

Monforte, AD ^{[1
]}

de Wolf, F ^{[1
]}

Egger, M ^{[1
]}

Fatkenheuer, G ^{[1
]}

Gill, J ^{[1
]}

Hogg, R ^{[1
]}

Justice, A ^{[1
]}

Ledergerber, B ^{[1
]}

Lundgren, J ^{[1
]}

May, M ^{[1
]}

Phillips, A ^{[1
]}

Reiss, P ^{[1
]}

Sabin, C ^{[1
]}

Staszewski, S ^{[1
]}

Sterne, J ^{[1
]}

Weller, I ^{[1
]}

May, M ^{[1
]}

Beckthold, B ^{[1
]}

Yip, B ^{[1
]}

Dauer, B ^{[1
]}

Fusco, J ^{[1
]}

Grabar, S ^{[1
]}

Lanoy, E ^{[1
]}

Junghans, C ^{[1
]}

Lavignolle, V ^{[1
]}

van Leth, F ^{[1
]}

Pereira, E ^{[1
]}

Pezzotti, P ^{[1
]}

Phillips, A ^{[1
]}

Sabin, C ^{[1
]}

Schmeisser, N ^{[1
]}

Billaud, E ^{[1
]}

Boué, F ^{[1
]}

Duval, X ^{[1
]}

Duvivier, C ^{[1
]}

Enel, P ^{[1
]}

Fournier, S ^{[1
]}

Gasnault, J ^{[1
]}

Gaud, C ^{[1
]}

Gilquin, J ^{[1
]}

Grabar, S ^{[1
]}

Khuong, MA ^{[1
]}

Lang, JM ^{[1
]}

Mary-Krause, M ^{[1
]}

Matheron, S ^{[1
]}

Meyohas, MC ^{[1
]}

Pialoux, G ^{[1
]}

Poizot-Martin, I ^{[1
]}

机构：

[1] IRCCS, Ist Nazl Malattie Infett L Spallanzani, Dipartimento Epidemiol, I-00149 Rome, Italy

来源：

CLINICAL INFECTIOUS DISEASES | 2005年 / 41卷 / 12期

基金：

英国医学研究理事会;

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background. We obtained estimates of the incidence of tuberculosis (TB) among patients receiving HAART and identified determinants of the incidence. Methods. We analyzed the incidence of TB during the first 3 years after initiation of HAART among 17,142 treatment-naive, AIDS- free persons starting HAART who were enrolled in 12 cohorts from Europe and North America. We used univariable and multivariable Poisson regression models to identify factors associated with the incidence. Results. During the first 3 years (36,906 person-years), 173 patients developed TB (incidence, 4.69 cases per 1000 person-years). In multivariable analysis, the incidence rate was lower for men who have sex with men, compared with injection drug users (relative rate, 2.46; 95% confidence interval [CI], 1.51-4.01), heterosexuals (relative rate, 2.42; 95% CI, 1.64-3.59), those with other suspected modes of transmission (relative rate, 1.66; 95% CI, 0.91-3.06), and those with a higher CD4(+) count at the time of HAART initiation (relative rate per log(2) cells/mL, 0.87; 95% CI, 0.84-0.91). During 28,846 person-years of follow-up after the first 6 months of HAART, 88 patients developed TB (incidence, 3.1 cases per 1000 person-years of follow-up). In multivariable analyses, a low baseline CD4(+) count (relative rate per log(2) cells/mL, 0.89; 95% CI, 0.83-0.96), 6-month CD4(+) count (relative rate per log(2) cells/mL, 0.90; 95% CI, 0.81-0.99), and a 6-month HIV RNA level 1400 copies/mL (relative rate, 2.21; 95% CI, 1.33-3.67) were significantly associated with the risk of acquiring TB after 6 months of HAART. Conclusion. The level of immunodeficiency at which HAART is initiated and the response to HAART are important determinants of the risk of TB. However, this risk remains appreciable even among those with a good response to HAART, suggesting that other interventions may be needed to control the TB epidemic in the HIV-infected population.

引用

页码：1772 / 1782

页数：11

共 50 条

[1] Anemia in HIV-infected patients receiving highly active antiretroviral therapy
Moore, RD
Forney, D
[J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 29 (01): : 54 - 57
[2] Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy
Curkendall, S. M.
Richardson, J. T.
Emons, M. F.
Fisher, A. E.
Everhard, F.
[J]. HIV MEDICINE, 2007, 8 (08) : 483 - 490
[3] Body composition in HIV-infected patients receiving highly active antiretroviral therapy
Chitu-Tisu, Cristina Emilia
Barbu, Ecaterina Constanta
Lazar, Mihai
Bojinca, Mihai
Tudor, Ana-Maria
Hristea, Adriana
Abagiu, Adrian Octavian
Ion, Daniela Adriana
Badarau, Anca Ioana
[J]. ACTA CLINICA BELGICA, 2017, 72 (01) : 55 - 62
[4] Arterial stiffness in HIV-infected patients receiving highly active antiretroviral therapy
Sevastianova, K
Sutinen, J
Westerbacka, J
Ristola, M
Yki-Järvinen, H
[J]. ANTIVIRAL THERAPY, 2005, 10 (08) : 925 - 935
[5] Osteonecrosis in six HIV-infected patients receiving highly active antiretroviral therapy
Molia, AC
Strady, C
Rouger, C
Beguinot, IM
Berger, JL
Trenque, TC
[J]. ANNALS OF PHARMACOTHERAPY, 2004, 38 (12) : 2050 - 2054
[6] Subdinical hypothyroidism in HIV-infected patients receiving highly active antiretroviral therapy
Calza, L
Manfredi, R
Chiodo, F
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 (03) : 361 - 363
[7] IMPACT OF TUBERCULOSIS ON MORTALITY AMONG HIV-INFECTED PATIENTS RECEIVING ANTIRETROVIRAL THERAPY
Chu, R.
Mills, E.
Beyene, J.
Bakanda, C.
Nachega, J.
Thabane, L.
[J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2011, 173 : S73 - S73
[8] Alternative therapy use in HIV-infected patients receiving highly active antiretroviral therapy
Risa, KJ
Nepon, L
Justis, JC
Panwalker, A
Berman, SM
Cinti, S
Wagener, MM
Singh, N
[J]. INTERNATIONAL JOURNAL OF STD & AIDS, 2002, 13 (10) : 706 - 713
[9] Incidence of pneumonia in HIV-infected patients in the highly active antiretroviral therapy era
Velasco Arribas, Maria
Satue Bartolome, Jose Angel
Losa Garcia, Juan Emilio
Espinosa Gimeno, Alfredo
Delgado-Iribarren, Alberto
Castilla Castellano, Virgilio
[J]. MEDICINA CLINICA, 2007, 128 (04): : 130 - 132
[10] Predictors of mortality among HIV-infected children receiving highly active antiretroviral therapy
Nlend, A. E. Njom
Loussikila, A. B.
[J]. MEDECINE ET MALADIES INFECTIEUSES, 2017, 47 (01): : 32 - 37

← 1 2 3 4 5 →